Rapid Diagnostic Systems LTD (NAOR)

We are developing NAOR, a rapid and decentralized isothermal molecular diagnostic platform. At its core, we use a one-step nucleic acid amplification method to multiply specific sequences of RNA, resulting in high sensitivity and specificity. The entire process is based on simple saliva samples and can be easily adopted to a variety of biological targets. We are initially addressing SARS-CoV-2 virus, the virus strain that causes COVID-19. The platform brings for the first time, high throughput, affordable, rapid, lab-grade detection to the field (e.g. schools, universities, airports, airplanes, borders, workplace), and also to at-home settings. Based on an enhanced variant of PCR and RT-LAMP, originally developed at the Israeli Technion, the multidisciplinary team created a platform that combines biochemistry, electronics, and artificial intelligence. The original clinical study (with results from Rambam Medical Center) was one of the first in the world to conduct a clinical study with rapid RNA testing of SARS-CoV-2. The company has since gathered significant data from around the world and further developed the technology, which is now being commercialized in select markets worldwide. “Professor Geva-Zatorsky and her team have provided a breakthrough in the global battle against the spread of COVID-19…. I can easily see this technology used not only in medical clinics, but also the workplace, at airports and eventually within our homes.” Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology & Medicine